Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction

Trial Profile

Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2014

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Heart failure
  • Focus Biomarker; Therapeutic Use
  • Acronyms ERIPE
  • Sponsors Menarini
  • Most Recent Events

    • 05 Apr 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 27 Oct 2012 Planned End Date changed from 18 Dec 2013 to 23 Apr 2014 as reported by European Clinical Trials Database.
    • 17 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top